Four EVERSANA Leaders Named to 2022 PM360 ELITE 100

On May 17, 2022 EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, reported four senior leaders have been named to the prestigious PM360 ELITE List for 2022 (Press release, EVERSANA, MAY 17, 2022, View Source [SID1234614724]). Now in its eighth year, the PM360 ELITE (Exceptional, Leaders, Innovators, Transformers, Entrepreneurs) represents the most influential people in the healthcare industry today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Lang, CEO, and Faruk Capan, Chief Innovation Officer and CEO of Intouch Group, an EVERSANA Company, were recognized together in the Transformational Leader category. Lang and Capan have closely worked together over the past six months as Intouch Group continues its integration with EVERSANA. Their combined vision to join forces to create a next-generation marketing agency for the pharmaceutical industry was announced in late 2021. This is the second consecutive year Lang has been named in this category.

Amy Peek, Executive Director, Talent Acquisition, Field Deployment Solutions, has been named in the Talent Acquisition Leader category. Amy leads the recruitment arm for EVERSANA’s field deployment team, which recruits and hires hundreds of pharmaceutical sales representatives, medical science liaisons and other deployment professionals each year for clients.

Nicholas Capanear, Senior Vice President and Executive Craft Director at Intouch Group, an EVERSANA Company, has been named in PM360’s Creative Director category. Capanear has helped the Intouch creative team reach new heights since joining the team in early 2021.

"It’s an honor to see colleagues across EVERSANA be recognized by their peers and industry publications like PM360 as industry leaders," said Jim Lang, CEO, EVERSANA. "Being named to this list speaks to each winner’s accomplishments while reinforcing the type of top talent we aspire to find and retain across our organization. Congrats to everyone on this year’s ELITE 100 list for your many contributions to the pharma industry."

The annual award recognizes individuals and teams who have made a significant impact on the life sciences and healthcare industries throughout their careers. Winners are profiled in PM360’s May 2022 issue, which can be found here.

Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference

On May 17, 2022 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022 (Press release, Protara Therapeutics, MAY 17, 2022, View Source [SID1234614723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The prerecorded presentation will become available on Tuesday, May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived for 90 days following the presentation.

Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

On May 17, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, reported that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022 (Press release, Selecta Biosciences, MAY 17, 2022, View Source [SID1234614722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

BridgeBio Pharma to Participate in May Investor Events

On May 17, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported that members of the management team will participate in the following upcoming investor conferences (Press release, BridgeBio, MAY 17, 2022, View Source [SID1234614721]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel, Virtual: Wednesday, May 18th at 2:30 pm ET
H. C. Wainwright Global Investment Conference, Virtual: Tuesday, May 24th at 7:00 am ET
UBS Global Healthcare Conference, New York, NY: Tuesday, May 24th at 11:30 am ET
J. P. Morgan West Coast Investor Day, San Francisco, CA: Tuesday, May 24th at 12:00 pm ET
To access more details on BridgeBio’s presentations, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at View Source

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

On May 17, 2022 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL (Press release, Aileron Therapeutics, MAY 17, 2022, View Source [SID1234614720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available under the Investors & Media section of the company’s website at investors.aileronrx.com. A replay of the webcast will be available on the Aileron website for approximately for 30 days following the presentation.